**e-References**

e-1. Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncol. 2014;16:589–593.

e-2. Abdallah A-O, Herlopian A, Ravilla R, et al. Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract. 2016;22:537–542.

e-3. Narumi Y, Yoshida R, Minami Y, et al. Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report. BMC Cancer. 2018;18:95.

e-4. Chang VA, Simpson DR, Daniels GA, Piccioni DE. Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation. J Immunother Cancer. 2018;6:153.

e-5. Wilson R, Menassa DA, Davies AJ, et al. Seronegative antibody-mediated neurology after immune checkpoint inhibitors. Ann Clin Transl Neurol. 2018;5:640–645.

e-6. Kubo K, Wadasaki K, Yamane H, Doi M. Radiation myelitis after durvalumab administration following chemoradiotherapy for locally advanced non-small cell lung cancer: an illustrative case report and review of the literature. Int Cancer Conf J. 2019;8:118–121.

e-7. Makkawi S, Brust T. Checkpoint inhibitor-induced longitudinally extensive transverse myelitis: a report on two cases (P719). ECTRIMS Online Libr. Epub 2019.

e-8. Carausu M, Beddok A, Langer A, et al. Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature. J Immunother Cancer. 2019;7:317.

e-9. Shimada T, Hoshino Y, Tsunemi T, et al. Neuromyelitis optica spectrum disorder after treatment with pembrolizumab. Mult Scler Relat Disord. 2020;37:101447.

e-10. Poretto V, Buganza M, Filipponi S, et al. Hunting the real culprit: a complex case of nivolumab-related myelitis. (P4.2-006). Neurology. 2019;92:P4.2-006.

e-11. Kunchok A, Zekeridou A, Pittock S. CRMP5-IgG–Associated Paraneoplastic Myelopathy With PD-L1 Inhibitor Therapy. JAMA Neurol. 2020;77:255.

e-12. Nowosielski M, Di Pauli F, Iglseder S, et al. Encephalomyeloneuritis and arthritis after treatment with immune checkpoint inhibitors. Neurol - Neuroimmunol Neuroinflammation. 2020;7:e773.

e-13. Brahmbhatt N, Dixit K. A Case Report of Recurrent Longitudinally Extensive Holocord Transverse Myelitis After Combination Immune Checkpoint Inhibitor Therapy with Nivolumab and Ipilimumab (815). Neurology. 2020;94:815.